TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Stress Reduction on Surgical Wound Healing: A Randomised Controlled Trial
Brief Summary: The purpose of this study is to investigate whether a stress reduction intervention prior to surgery can improve wound healing and recovery.The investigators hypothesise that patients who receive a psychological stress reduction intervention prior to surgery will report lower stress and higher perceived control, have lower stress hormones, better wound healing and better self-reported recovery than patients who receive standard care alone.


Options:
A: Arm Label: Cognitive behavioral therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioral therapy | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy; Assigned to Arm(s): Cognitive behavioral therapy
B: Arm Label: Audio Relaxation technique; Type: EXPERIMENTAL; Interventions: Behavioral: Audio Relaxation Technique | Arm Label: Medical Music Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Medical Music Intervention | Arm Label: Nature Therapy without Music; Type: EXPERIMENTAL; Interventions: Behavioral: Nature Therapy without Music | Arm Label: Nature Therapy with Music; Type: EXPERIMENTAL; Interventions: Behavioral: Nature Therapy with Music | Intervention Type: BEHAVIORAL; Name: Audio Relaxation Technique; Assigned to Arm(s): Audio Relaxation technique | Intervention Type: BEHAVIORAL; Name: Medical Music Intervention; Assigned to Arm(s): Medical Music Intervention | Intervention Type: BEHAVIORAL; Name: Nature Therapy without Music; Assigned to Arm(s): Nature Therapy without Music | Intervention Type: BEHAVIORAL; Name: Nature Therapy with Music; Assigned to Arm(s): Nature Therapy with Music
C: Arm Label: etomidate/sevoflurane; Type: ACTIVE_COMPARATOR; Interventions: Other: control, Other: suggestion, Other: dreamfilm | Arm Label: propofol/sevoflurane; Type: ACTIVE_COMPARATOR; Interventions: Other: control, Other: suggestion, Other: dreamfilm | Arm Label: propofol/propofol; Type: ACTIVE_COMPARATOR; Interventions: Other: control, Other: suggestion, Other: dreamfilm | Intervention Type: OTHER; Name: control; Assigned to Arm(s): etomidate/sevoflurane, propofol/propofol, propofol/sevoflurane | Intervention Type: OTHER; Name: suggestion; Assigned to Arm(s): etomidate/sevoflurane, propofol/propofol, propofol/sevoflurane | Intervention Type: OTHER; Name: dreamfilm; Assigned to Arm(s): etomidate/sevoflurane, propofol/propofol, propofol/sevoflurane
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Stress reduction intervention | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Stress reduction intervention; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Brief Summary: The purpose of this study is to determine if gastric/esophageal, lung, pancreatic, bladder and sarcoma patients show benefit from brivanib treatment. Patients who clearly do, stay on treatment. Those in which it is unclear will be randomized to continue or withdraw treatment to determine whether that benefit is related to brivanib


Options:
A: Arm Label: Cyclophosphamide and BIBF-1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120 | Arm Label: Cyclophosphamide and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIBF 1120 | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): Cyclophosphamide and BIBF-1120, Cyclophosphamide and placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: brivanib | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: brivanib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Aflibercept 2.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Arm Label: Aflibercept 4.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept 4.0 mg/kg | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept 2.0 mg/kg
D: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Experimental

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Brief Summary: The purpose of this study is to determine if gastric/esophageal, lung, pancreatic, bladder and sarcoma patients show benefit from brivanib treatment. Patients who clearly do, stay on treatment. Those in which it is unclear will be randomized to continue or withdraw treatment to determine whether that benefit is related to brivanib


Options:
A: Arm Label: A (reference); Type: PLACEBO_COMPARATOR; Interventions: N/A | Arm Label: B (concurrent cediranib); Type: ACTIVE_COMPARATOR; Interventions: Drug: cediranib | Arm Label: C (concurrent and maintenance cediranib); Type: ACTIVE_COMPARATOR; Interventions: Drug: cediranib | Intervention Type: DRUG; Name: cediranib; Assigned to Arm(s): B (concurrent cediranib), C (concurrent and maintenance cediranib)
B: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Experimental
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: brivanib | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: brivanib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: Arm C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: AMG 386 Placebo | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): Arm C

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Personality disorders are life-long maladaptive behavioral patterns. Borderline personality disorder (BPD) is the leading personality disorder encountered in clinical settings, often associated with tremendous distress. It is characterized by impulsivity, emotional lability, unstable interpersonal relationships, with particular sensitivity to abandonment. BPD patients are prone to self destructive behaviors and all too frequently attempt suicide. When in emotional turmoil, persons with BPD may also develop brief, transient psychotic states.

Psychotherapy for BPD is a common treatment option, but it requires considerable time and specific personnel training, and is therefore not always feasible. Medical treatment is an efficacious alternative, however there is no concensus on drug selection. Some experts have suggested that medical treatment should be selected individually according to the subject's dominant clinical symptom. Several psychopharmacological groups have been proposed: Antidepressants, mood stabilizers, and several novel antipsychotic drugs. The latter are particularly promising since they may produce symptomaic improvement with fewer adverse effects. Risperidone has been shown in a few preliminary studies to be promising in the treatment of various BPD symptoms, but no controlled study has tested it yet. We propose to test the efficacy of risperidone in the treatment of BPD in a double-blind crossover design using both clinical and phsysiological measure.The main hypothesis is that risperidone will be efficient in alleviating BPD core and secondary symptoms.


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Device: Active tDCS, Device: Sham tDCS | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Device: Active tDCS, Device: Sham tDCS | Intervention Type: DEVICE; Name: Active tDCS; Assigned to Arm(s): Group 1, Group 2 | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Group 1, Group 2
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Omega 3 fatty acids | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Omega 3 fatty acids | Intervention Type: DRUG; Name: Omega 3 fatty acids; Assigned to Arm(s): A, B
C: Arm Label: Relaxation group; Type: ACTIVE_COMPARATOR; Interventions: Other: Relaxation group | Arm Label: Psychoeducational group; Type: EXPERIMENTAL; Interventions: Behavioral: Interventional group : PEPSUI psychoeducational program | Intervention Type: BEHAVIORAL; Name: Interventional group : PEPSUI psychoeducational program; Assigned to Arm(s): Psychoeducational group | Intervention Type: OTHER; Name: Relaxation group; Assigned to Arm(s): Relaxation group
D: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Controlled Trial of Intubation With the McGrath Series 5 Video Laryngoscope vs the Macintosh Laryngoscope
Brief Summary: The simplicity of use and intuitive function of the McGrath video-laryngoscope suggests it may have a bigger role than as a back-up to conventional direct laryngoscopy and could possibly be the first-line laryngoscope for situations where difficult intubations are more likely or more hazardous. The incidence of difficult or failed intubation for an individual anaesthetist is related to their experience, decreasing as experience increases. The purpose of this trial is to evaluate the McGrath laryngoscope when used by relatively inexperienced anaesthetists, who are those most likely to encounter difficulties.

The null hypotheses to be tested is that there is no difference between the Macintosh and McGrath laryngoscope in terms of ease and success in intubation.


Options:
A: Arm Label: Direct Laryngoscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Direct Laryngoscopy | Arm Label: CMAC; Type: EXPERIMENTAL; Interventions: Procedure: CMAC videolaryngoscope | Intervention Type: PROCEDURE; Name: CMAC videolaryngoscope; Assigned to Arm(s): CMAC | Intervention Type: PROCEDURE; Name: Direct Laryngoscopy; Assigned to Arm(s): Direct Laryngoscopy
B: Arm Label: INTUBATION; Type: OTHER; Interventions: Procedure: INTUBATION IN INTENSIVE CARE UNIT | Intervention Type: PROCEDURE; Name: INTUBATION IN INTENSIVE CARE UNIT; Assigned to Arm(s): INTUBATION
C: Arm Label: Macintosh Direct Laryngoscope; Type: ACTIVE_COMPARATOR; Interventions: Device: Intubation with GlideScope Video Laryngoscope or Macintosh Direct Laryngoscope | Arm Label: GlideScope Video Laryngoscope; Type: ACTIVE_COMPARATOR; Interventions: Device: Intubation with GlideScope Video Laryngoscope or Macintosh Direct Laryngoscope | Intervention Type: DEVICE; Name: Intubation with GlideScope Video Laryngoscope or Macintosh Direct Laryngoscope; Assigned to Arm(s): GlideScope Video Laryngoscope, Macintosh Direct Laryngoscope
D: Arm Label: Intubation c McGrath videolaryngoscope; Type: ACTIVE_COMPARATOR; Interventions: Device: McGrath | Arm Label: Intubation using Macintosh Laryngoscope; Type: ACTIVE_COMPARATOR; Interventions: Device: Tracheal intubation using Macintosh Laryngoscope | Intervention Type: DEVICE; Name: McGrath; Assigned to Arm(s): Intubation c McGrath videolaryngoscope | Intervention Type: DEVICE; Name: Tracheal intubation using Macintosh Laryngoscope; Assigned to Arm(s): Intubation using Macintosh Laryngoscope

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Controlled Trial of Intubation With the McGrath Series 5 Video Laryngoscope vs the Macintosh Laryngoscope
Brief Summary: The simplicity of use and intuitive function of the McGrath video-laryngoscope suggests it may have a bigger role than as a back-up to conventional direct laryngoscopy and could possibly be the first-line laryngoscope for situations where difficult intubations are more likely or more hazardous. The incidence of difficult or failed intubation for an individual anaesthetist is related to their experience, decreasing as experience increases. The purpose of this trial is to evaluate the McGrath laryngoscope when used by relatively inexperienced anaesthetists, who are those most likely to encounter difficulties.

The null hypotheses to be tested is that there is no difference between the Macintosh and McGrath laryngoscope in terms of ease and success in intubation.


Options:
A: Arm Label: Intubation c McGrath videolaryngoscope; Type: ACTIVE_COMPARATOR; Interventions: Device: McGrath | Arm Label: Intubation using Macintosh Laryngoscope; Type: ACTIVE_COMPARATOR; Interventions: Device: Tracheal intubation using Macintosh Laryngoscope | Intervention Type: DEVICE; Name: McGrath; Assigned to Arm(s): Intubation c McGrath videolaryngoscope | Intervention Type: DEVICE; Name: Tracheal intubation using Macintosh Laryngoscope; Assigned to Arm(s): Intubation using Macintosh Laryngoscope
B: Arm Label: Laryngoscopy; Type: OTHER; Interventions: Procedure: Endotracheal Intubation | Arm Label: Videolaryngoscopy; Type: OTHER; Interventions: Procedure: Endotracheal Intubation | Intervention Type: PROCEDURE; Name: Endotracheal Intubation; Assigned to Arm(s): Laryngoscopy | Intervention Type: PROCEDURE; Name: Endotracheal Intubation; Assigned to Arm(s): Videolaryngoscopy
C: Arm Label: Truview EVO2®; Type: ACTIVE_COMPARATOR; Interventions: Other: Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes | Arm Label: Airtraq®; Type: ACTIVE_COMPARATOR; Interventions: Other: Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes | Arm Label: Direct laryngoscopy; Type: ACTIVE_COMPARATOR; Interventions: Other: Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes | Intervention Type: OTHER; Name: Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes; Assigned to Arm(s): Airtraq®, Direct laryngoscopy, Truview EVO2®
D: Arm Label: Conventional Glidescope; Type: ACTIVE_COMPARATOR; Interventions: Device: Conventional (reusable) Glidescope | Arm Label: Single-use Glidescope; Type: EXPERIMENTAL; Interventions: Device: Single-use Glidescope videolaryngoscope | Intervention Type: DEVICE; Name: Conventional (reusable) Glidescope; Assigned to Arm(s): Conventional Glidescope | Intervention Type: DEVICE; Name: Single-use Glidescope videolaryngoscope; Assigned to Arm(s): Single-use Glidescope

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Safety and Efficacy Trial Evaluating the Use of Apixaban for the Extended Treatment of Deep Vein Thrombosis and Pulmonary Embolism
Brief Summary: The purpose is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients who have completed their intended treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE)


Options:
A: Arm Label: dabigatran etexilate 150 mg BID; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg twice daily (BID) | Arm Label: matching placebo twice daily (BID); Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo twice daily (BID) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg twice daily (BID); Assigned to Arm(s): dabigatran etexilate 150 mg BID | Intervention Type: DRUG; Name: matching placebo twice daily (BID); Assigned to Arm(s): matching placebo twice daily (BID)
B: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin
C: Arm Label: dabigatran etexilate 150 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg | Arm Label: warfarin (INR 2-3); Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin (INR 2-3) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg; Assigned to Arm(s): dabigatran etexilate 150 mg | Intervention Type: DRUG; Name: warfarin (INR 2-3); Assigned to Arm(s): warfarin (INR 2-3)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Safety and Efficacy Trial Evaluating the Use of Apixaban for the Extended Treatment of Deep Vein Thrombosis and Pulmonary Embolism
Brief Summary: The purpose is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients who have completed their intended treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE)


Options:
A: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin
B: Arm Label: dabigatran etexilate 150 mg BID; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg twice daily (BID) | Arm Label: matching placebo twice daily (BID); Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo twice daily (BID) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg twice daily (BID); Assigned to Arm(s): dabigatran etexilate 150 mg BID | Intervention Type: DRUG; Name: matching placebo twice daily (BID); Assigned to Arm(s): matching placebo twice daily (BID)
C: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Safety and Efficacy Trial Evaluating the Use of Apixaban for the Extended Treatment of Deep Vein Thrombosis and Pulmonary Embolism
Brief Summary: The purpose is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients who have completed their intended treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE)


Options:
A: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin
B: Arm Label: edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: enoxaparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate; Assigned to Arm(s): edoxaban tosylate | Intervention Type: DRUG; Name: enoxaparin/unfractionated heparin; Assigned to Arm(s): heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin
C: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3

Answer: D